This question is based primarily on the fundamental changes in the COVID-19 coagulopathy already described above, and the induced hypercoagulable state in patients with COVID-19, suggesting the production of aPL antibodies and subsequent cAPS could be the cause of thrombosis as a previously unrecognized mechanism in critical disease states [31]. Here, FASLG is linked to COVID-19.